- Home
- About
- Find staff
- Markus Axelsson
Markus Axelsson
Docent
Department of Clinical-
Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center
study
Magnus Johnsson, Y. T. Stenberg, H. H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmeström, Sofia Sandgren, Igal Rosenstein, Jan Lycke, Markus Axelsson, Lenka Novakova
MULTIPLE SCLEROSIS JOURNAL - 2024 -
Medically unexplained symptoms are common in women in tertiary neurological healthcare center: A survey cohort study of persons investigated for suspected multiple
sclerosis
Lenka Novakova, Anna Karin Hedstrom, Markus Axelsson, Anne Brandt, Lars Alfredsson, Tomas Olsson, Jan Lycke
BRAIN AND BEHAVIOR - 2024 -
High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple
sclerosis
Simone Hjæresen, Eirikur Benedikz, Tobias Sejbaek, Markus Axelsson, Lenka Novakova, Mengliang Zhang, Jan Lycke, Zsolt Illes, Åsa Fex-Svenningsen
Journal of the Neurological Sciences - 2024 -
Neurofilament light, glial fibrillary acidic protein, and tau in a regional epilepsy cohort: High plasma levels are rare but related to
seizures
Sarah Akel, Fredrik Asztely, Rakesh Kumar Banote, Markus Axelsson, Henrik Zetterberg, Johan Zelano
Epilepsia - 2023 -
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple
sclerosis
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Clas Malmeström, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Journal of Neurology - 2023 -
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple
sclerosis.
Sofia Sandgren, Lenka Nováková Nyrén, Anna Nordin, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
Frontiers in neurology - 2023 -
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying
therapies
M. Rabenstein, O. G. Thomas, G. Carlin, M. Khademi, K. A. Högelin, Clas Malmeström, Markus Axelsson, Anne Brandt, G. Gafvelin, H. Grönlund, I. Kockum, F. Piehl, Jan Lycke, T. Olsson, T. Hessa
European Journal of Neurology - 2023 -
Presence of neural surface and onconeural autoantibodies in cerebrospinal fluid and serum in neurological diseases presents a potential risk for
misdiagnosis
Oskar Stevens-Jones, Clas Malmeström, Clara Constantinescu, Keti Dalla, Bengt Nellgård, Johan Zelano, Radu Constantinescu, Markus Axelsson
European Journal of Neurology - 2023 -
CYBA allelic variants are associated with severity and recovery in Guillain-Barré
syndrome
Andreas Törnell, Nina Lagerström, Natalia Mossberg, Roberta Kiffin, Helen H. Farman, Jan Lycke, Oluf Andersen, Markus Axelsson, Kristoffer Hellstrand, Anna Martner
Journal of the peripheral nervous system - 2023 -
Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple
sclerosis.
Lenka Novakova, Marcus Henricsson, Elias Björnson, Markus Axelsson, Jan Borén, Igal Rosenstein, Jan Lycke, Susanna Cardell, Maria K. Blomqvist
Multiple sclerosis and related disorders - 2023 -
A prospective feasibility trial exploring novel biomarkers for neurotoxicity after isolated limb
perfusion
Anna Corderfeldt, Markus Axelsson, G. Bragadottir, Kaj Blennow, Henrik Zetterberg, Roger Olofsson Bagge
Perfusion-Uk - 2023 -
Paraneoplastic or not? Sirtuin 2 in anti-N-methyl-D-aspartate receptor
encephalitis
Oskar Stevens-Jones, H. Mojzisova, M. Elisak, Radu Constantinescu, J. Hanzalova, Markus Axelsson, David Krysl
European Journal of Neurology - 2023 -
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective
survey
Sofia Sandgren, Lenka Novakova, Markus Axelsson, Firoozeh Amirbeagi, I. Kockum, T. Olsson, Clas Malmeström, Jan Lycke
Frontiers in Neurology - 2023 -
High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple
sclerosis
Igal Rosenstein, Markus Axelsson, Lenka Novakova, S. Rasch, Kaj Blennow, Henrik Zetterberg, Jan Lycke
FRONTIERS IN IMMUNOLOGY - 2023 -
Decreased incidence of Guillain-Barre syndrome during the COVID-19 pandemic: a retrospective population-based
study
Brynhildur Hafsteinsdottir, Ellen Dalemo, O. Eliasdottir, E. Olafsson, Markus Axelsson
Neuroepidemiology - 2023 -
MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple
sclerosis
S. Hjaeresen, T. Sejbaek, Markus Axelsson, S. K. Mortensen, H. Vinslov-Jensen, G. Pihl-Jensen, Lenka Novakova, C. B. Pedersen, B. Halle, F. R. Poulsen, M. L. Zhang, E. Benedikz, J. L. Frederiksen, Jan Lycke, Z. Illes, A. Fex-Svenningsen
Journal of the Neurological Sciences - 2022 -
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled
trial
A. Svenningsson, T. Frisell, J. Burman, J. Salzer, K. Fink, S. Hallberg, J. Hambraeus, Markus Axelsson, F. Al Nimer, P. Sundstrom, M. Gunnarsson, R. Johansson, J. Mellergard, Igal Rosenstein, A. Ayad, I. Sjoblom, A. Risedal, P. de Flon, Eric Gilland, J. Lindeberg, F. Shawket, F. Piehl, Jan Lycke
Lancet Neurology - 2022 -
Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple
sclerosis
Igal Rosenstein, S. Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Frontiers in Immunology - 2022 -
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of
natalizumab
Magnus Johnsson, Helen H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmeström, Markus Axelsson, Jan Lycke
Multiple Sclerosis Journal - 2022 -
Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot
study
Kalle Johansson, Pontus Wasling, Lenka Novakova, S. Sjodin, Ann Brinkmalm, Gunnar Brinkmalm, Kaj Blennow, Henrik Zetterberg, Markus Axelsson
Multiple Sclerosis and Related Disorders - 2022 -
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated
disorder
Magnus Johnsson, Fredrik Asztely, S. Hejnebo, Markus Axelsson, Clas Malmeström, T. Olausson, Jan Lycke
Annals of Clinical and Translational Neurology - 2022 -
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based
study
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Multiple Sclerosis Journal - 2022 -
Follow-up after infectious mononucleosis in search of serological similarities with presymptomatic multiple
sclerosis
Daniel Jons, Linn Persson Berg, P. Sundstrom, Sara Haghighi, Markus Axelsson, M. Thulin, Tomas Bergström, Oluf Andersen
Multiple Sclerosis and Related Disorders - 2021 -
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world
investigation
Igal Rosenstein, S. Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Journal of Neurochemistry - 2021 -
A multicentre validation study of the diagnostic value of plasma neurofilament
light.
Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat, Antoine Leuzy, Emma L van der Ende, Thomas Karikari, Andrea L Benedet, Tharick A Pascoal, Alberto Lleó, Lucilla Parnetti, Daniela Galimberti, Laura Bonanni, Andrea Pilotto, Alessandro Padovani, Jan Lycke, Lenka Novakova, Markus Axelsson, Latha Velayudhan, Gil D Rabinovici, Bruce Miller, Carmine Pariante, Naghmeh Nikkheslat, Susan M Resnick, Madhav Thambisetty, Michael Schöll, Gorka Fernández-Eulate, Francisco J Gil-Bea, Adolfo López de Munain, Ammar Al-Chalabi, Pedro Rosa-Neto, Andre Strydom, Per Svenningsson, Erik Stomrud, Alexander Santillo, Dag Aarsland, John C van Swieten, Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Abdul Hye, Oskar Hansson
Nature communications - 2021 -
Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of
life
Clara Constantinescu, Lenka Novakova, Clas Malmeström, Radu Constantinescu, Markus Axelsson, Jan Lycke
Multiple Sclerosis and Related Disorders - 2021 -
The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple
sclerosis
S. Hjaeresen, T. Sejbaek, Markus Axelsson, H. Vinslov-Jensen, S. K. Mortensen, G. Pihl-Jensen, Lenka Novakova, J. D. R. Christensen, C. B. Pedersen, B. Halle, F. R. Poulsen, J. L. Frederiksen, M. L. Zhang, E. Benedikz, Jan Lycke, Z. Illes, A. F. Svenningsen
Journal of Neurology - 2021 -
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: An observational
study
Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, Sigrun Einarsdottir, Andreas Tolf, Anne Marie Landtblom, Lenka Novakova, Markus Axelsson, Clas Malmeström, Honar Cherif, Kristina Carlson, Jan Lycke, Joachim Burman
Journal of Neurology, Neurosurgery and Psychiatry - 2021 -
Inflammation-related plasma and CSF biomarkers for multiple
sclerosis
J. Huang, M. Khademi, L. Fugger, O. Lindhe, Lenka Novakova, Markus Axelsson, Clas Malmeström, Clara Constantinescu, Jan Lycke, F. Piehl, T. Olsson, I. Kockum
Proceedings of the National Academy of Sciences of the United States of America - 2020 -
Intrathecal immunoreactivity in people with or without previous infectious
mononucleosis.
Daniel Jons, Henrik Zetterberg, Clas Malmeström, Tomas Bergström, Markus Axelsson, Kaj Blennow, Måns Thulin, Peter Sundström, Oluf Andersen
Acta neurologica Scandinavica - 2020 -
Neuronal antibodies in adult patients with new-onset seizures: A prospective
study
Johan Zelano, Markus Axelsson, Radu Constantinescu, Clas Malmeström, E. Kumlien
Brain and Behavior - 2019 -
Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological
diseases
Radu Constantinescu, Ubah Mahamud, Clara Constantinescu, Barbro Eriksson, Lenka Novakova, Bob Olsson, Lars Rosengren, Kaj Blennow, Markus Axelsson
Acta Neurologica Scandinavica - 2019 -
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and
Meta-analysis.
Claire Bridel, Wessel N van Wieringen, Henrik Zetterberg, Betty M Tijms, Charlotte E Teunissen, José C Alvarez-Cermeño, Ulf Andreasson, Markus Axelsson, David C Bäckström, Ales Bartos, Maria Bjerke, Adam Boxer, Lou Brundin, Joachim Burman, Tove Christensen, Lenká Fialová, Lars Forsgren, Jette L Frederiksen, Magnus Gisslén, Elizabeth Gray, Martin Gunnarsson, Sara Hall, Oskar Hansson, Megan Herbert, Joel Jakobsson, Jan Jessen-Krut, Shorena Janelidze, Gudmundur Johannsson, Michael Jonsson, Ludwig Kappos, Mohsen Khademi, Michael Khalil, Jens Kuhle, Mikael Landén, Ville Leinonen, Giancarlo Logroscino, Ching-Hua Lu, Jan Lycke, Nadia K Magdalinou, Andrea Malaspina, Niklas Mattsson, Lieke H Meeter, Sanjay R Mehta, Signe Modvig, Tomas Olsson, Ross W Paterson, Josué Pérez-Santiago, Fredrik Piehl, Yolande A L Pijnenburg, Okko T Pyykkö, Oskar Ragnarsson, Julio C Rojas, Jeppe Romme Christensen, Linda Sandberg, Carole S Scherling, Jonathan M Schott, Finn T Sellebjerg, Isabella L Simone, Tobias Skillbäck, Morten Stilund, Peter Sundström, Anders Svenningsson, Rosanna Tortelli, Carla Tortorella, Alessandro Trentini, Maria Troiano, Martin R Turner, John C van Swieten, Mattias Vågberg, Marcel M Verbeek, Luisa M Villar, Pieter Jelle Visser, Anders Wallin, Andreas Weiss, Carsten Wikkelsö, Edward J Wild, Kaj Blennow
JAMA neurology - 2019 -
A SCA7 premutation may be a novel Mendelian modifier of MS course: A case
report
Christina Sundal, Markus Axelsson, L. Wiklund, Christopher Lindberg, Oluf Andersen
Multiple Sclerosis and Related Disorders - 2019 -
Cerebrospinal fluid NCAM levels are modulated by disease-modifying
therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni, Jan Lycke, S. Gnanapavan
Acta Neurologica Scandinavica - 2019 -
Natalizumab, rituximab and fingolimod as escalation therapy in multiple
sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell, A. Svenningsson, Jan Lycke, F. Piehl, J. Selzer
European Journal of Neurology - 2019 -
Cerebrospinal fluid growth-associated protein 43 in multiple
sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova, Vesna Kostanjevecki, Manu Vandijck, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Scientific reports - 2019 -
Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in
parkinsonism
Radu Constantinescu, Lage Rosengren, Barbro Eriksson, Kaj Blennow, Markus Axelsson
Acta Neurologica Scandinavica - 2019 -
Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting
MS
Lenka Novakova, Avadhesh Kumar Singh, Markus Axelsson, Marcus Ståhlman, Martin Adiels, Clas Malmeström, Henrik Zetterberg, Jan Borén, Jan Lycke, Susanna Cardell, Maria K. Blomqvist
Journal of Neurochemistry - 2018 -
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of
biomarkers.
Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Imberg, Henrik Zetterberg, Olle Nerman, Jan Lycke
PloS one - 2018 -
Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot
study.
Markus Axelsson, Magnus Sjögren, Oluf Andersen, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Acta neurologica Scandinavica - 2018 -
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple
sclerosis.
Lenka Nováková Nyrén, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Tomas Olsson, Jan Lycke
Journal of neurochemistry - 2017 -
Monitoring disease activity in multiple sclerosis using serum neurofilament light
protein.
Lenka Novakova, Henrik Zetterberg, Peter Sundström, Markus Axelsson, Martin Gunnarsson, Clas Malmeström, Fredrik Piehl, Kaj Blennow, Jan Lycke
Neurology - 2017 -
Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying
malignancies.
Radu Constantinescu, Fredrik Asztély, Filip Bergquist, Henrik Zetterberg, Ulf Andreasson, Markus Axelsson, Elinor Ben-Menachem, Daniel Jons, Clas Malmeström, Lars Rosengren, Kaj Blennow
Journal of neuroimmunology - 2017 -
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple
sclerosis.
Lenka Novakova, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Thomas Olsson, Jan Lycke
Multiple sclerosis (Houndmills, Basingstoke, England) - 2017 -
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological
Society
M. Vagberg, Markus Axelsson, R. Birgander, J. Burman, C. Cananau, Y. Forslin, T. Granberg, M. Gunnarsson, A. von Heijne, Lars Jönsson, V. D. Karrenbauer, E. M. Larsson, T. Lindqvist, Jan Lycke, L. Lonn, E. Mentesidou, S. Muller, P. Nilsson, F. Piehl, A. Svenningsson, M. Vrethem, J. Wikstrom
Acta Neurologica Scandinavica - 2017 -
High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple
Sclerosis.
Avadhesh Kumar Singh, Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke, Susanna Cardell
Frontiers in Immunology - 2017 -
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or
mitoxantrone.
Annika Öhrfelt, Markus Axelsson, Clas Malmeström, Lenka Novakova, Amanda Heslegrave, Kaj Blennow, Jan Lycke, Henrik Zetterberg
Multiple sclerosis (Houndmills, Basingstoke, England) - 2016 -
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis
Patients
P. Alping, T. Frisell, Lenka Novakova, P. Islam-Jakobsson, J. Salzer, A. Bjorck, Markus Axelsson, Clas Malmeström, K. Fink, Jan Lycke, A. Svenningsson, F. Piehl
Annals of Neurology - 2016 -
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple
sclerosis.
Joachim Burman, Raili Raininko, Kaj Blennow, Henrik Zetterberg, Markus Axelsson, Clas Malmeström
Journal of neuroimmunology - 2016 -
Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune
encephalitis
Radu Constantinescu, David Krysl, Filip Bergquist, Kerstin Andrén, Clas Malmeström, Fredrik Asztely, Markus Axelsson, Elinor Ben-Menachem, Kaj Blennow, Lars Rosengren, Henrik Zetterberg
European Journal of Neurology - 2016 -
Rituximab in multiple
sclerosis
J. Salzer, R. Svenningsson, P. Alping, Lenka Novakova, A. Björck, K. Fink, P. Islam-Jakobsson, Clas Malmeström, Markus Axelsson, M. Vågberg, P. Sundström, Jan Lycke, F. Piehl, A. Svenningsson
Neurology - 2016 -
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple
sclerosis.
Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Ingemar Björkhem, Virginija Danylaité Karrenbauer, Jan Lycke
Journal of the Neurological Sciences - 2015 -
Immunosuppressive therapy reduces axonal damage in progressive multiple
sclerosis.
Markus Axelsson, Clas Malmeström, Martin Gunnarsson, Henrik Zetterberg, Peter Sundström, Jan Lycke, Anders Svenningsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2014 -
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive
treatment.
Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob Olsson
Journal of neuroimmunology - 2014 -
MS risk genes are transcriptionally regulated in CSF leukocytes at
relapse
Margareta Jernås, Clas Malmeström, Markus Axelsson, Caroline Olsson, Intawat Nookaew, Hans Wadenvik, Henrik Zetterberg, Kaj Blennow, Jan Lycke, Mats Rudemo, Bob Olsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple
sclerosis.
Markus Axelsson, Niklas Mattsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
Journal of Neuroimmunology - 2013 -
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple
sclerosis
J Kuhle, Clas Malmeström, Markus Axelsson, K Plattner, O Yaldizli, T Derfuss, G Giovannoni, L Kappos, Jan Lycke
Acta neurologica Scandinavica - 2013 -
Serum levels of LIGHT in
MS
Clas Malmeström, Alan Gillett, Margareta Jernås, Mohsen Khademi, Markus Axelsson, Ingrid Kockum, Niklas Mattsson, Henrik Zetterberg, Kaj Blennow, Lars Alfredsson, Hans Wadenvik, Jan Lycke, Tomas Olsson, Bob Olsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple
sclerosis.
Kristin Augutis, Markus Axelsson, Erik Portelius, Gunnar Brinkmalm, Ulf Andreasson, Mikael K Gustavsson, Clas Malmeström, Jan Lycke, Kaj Blennow, Henrik Zetterberg, Niklas Mattsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
MicroRNA regulate immune pathways in T-cells in multiple sclerosis
(MS)
Margareta Jernås, Clas Malmeström, Markus Axelsson, Intawat Nookaew, Hans Wadenvik, Jan Lycke, Bob Olsson
BMC Immunology - 2013 -
Axonal damage in relapsing multiple sclerosis is markedly reduced by
natalizumab.
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, Peter Sundström, Charlotte Dahle, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Niklas Norgren, Lars Rosengren, Anders Svenningsson, Jan Lycke
Annals of neurology - 2011